Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

GlobeNewswire 3 days ago

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire April 18, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire April 16, 2024

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

GlobeNewswire April 2, 2024

PharmaTher's Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

GlobeNewswire February 21, 2024

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

GlobeNewswire February 12, 2024

PharmaTher Provides Update for Expected FDA Approval of Ketamine

GlobeNewswire January 10, 2024

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX(TM) (Ketamine)

GlobeNewswire September 27, 2023

PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX(TM) (Ketamine) to the FDA

GlobeNewswire September 6, 2023

PharmaTher Announces Positive Research Results for PharmaPatch(TM) with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics

GlobeNewswire July 18, 2023

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX(TM) (racemic ketamine) to the FDA

GlobeNewswire June 27, 2023

PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX(TM) (racemic ketamine) in the U.S.

GlobeNewswire June 20, 2023

PharmaTher Holdings Provides Corporate Update

GlobeNewswire June 12, 2023

PharmaTher Holdings Submits Fast Track Application to FDA for KETARX(TM) (Ketamine) for the Treatment of Parkinson's Disease

GlobeNewswire May 2, 2023

Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech

GlobeNewswire April 3, 2023

PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX(TM) (Ketamine) in Parkinson's Disease

GlobeNewswire March 29, 2023

PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX(TM) (Ketamine) On-Body Pump System

GlobeNewswire February 7, 2023

Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development

GlobeNewswire February 6, 2023

PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX(TM) (Ketamine) for the Treatment of Rett Syndrome

GlobeNewswire February 2, 2023

PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX(TM) (Ketamine) in Parkinson's Disease

GlobeNewswire February 1, 2023